Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find ...

KalVista's sebetralstat shows strong phase 3 results for HAE, but financial concerns and competition make investing cautious. Click here to read more.

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Navenibart is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting attack prevention for HAE. Initial results from the Phase 1b/2 ALPHA-STAR clinical trial of ...

Research Triangle Park, North Carolina Tuesday, November 19, 2024, 16:00 Hrs [IST] ...

One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. U.S. Indication and Important Safety Information INDICATION ORLADEYO ® (berotralstat) is a ...